- Home
- CHRS vs SVII Comparison
CHRS vs SVII Comparison
Compare CHRS & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SVII
- Stock Information
- Founded
- CHRS 2010
- SVII 2021
- Country
- CHRS United States
- SVII United States
- Employees
- CHRS 177
- SVII N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SVII Blank Checks
- Sector
- CHRS Health Care
- SVII Finance
- Exchange
- CHRS Nasdaq
- SVII Nasdaq
- Market Cap
- CHRS 149.9M
- SVII 117.1M
- IPO Year
- CHRS 2014
- SVII 2022
- Fundamental
- Price
- CHRS $1.37
- SVII $12.09
- Analyst Decision
- CHRS Strong Buy
- SVII
- Analyst Count
- CHRS 4
- SVII 0
- Target Price
- CHRS $4.51
- SVII N/A
- AVG Volume (30 Days)
- CHRS 1.4M
- SVII 38.2K
- Earning Date
- CHRS 11-05-2025
- SVII 01-01-0001
- Dividend Yield
- CHRS N/A
- SVII N/A
- EPS Growth
- CHRS N/A
- SVII N/A
- EPS
- CHRS 1.55
- SVII 0.17
- Revenue
- CHRS $272,209,000.00
- SVII N/A
- Revenue This Year
- CHRS N/A
- SVII N/A
- Revenue Next Year
- CHRS $126.00
- SVII N/A
- P/E Ratio
- CHRS $0.88
- SVII $72.16
- Revenue Growth
- CHRS 52.33
- SVII N/A
- 52 Week Low
- CHRS $0.66
- SVII $11.16
- 52 Week High
- CHRS $2.43
- SVII $12.74
- Technical
- Relative Strength Index (RSI)
- CHRS 73.83
- SVII 53.94
- Support Level
- CHRS $1.26
- SVII $11.97
- Resistance Level
- CHRS $1.39
- SVII $12.09
- Average True Range (ATR)
- CHRS 0.08
- SVII 0.14
- MACD
- CHRS 0.02
- SVII -0.01
- Stochastic Oscillator
- CHRS 94.10
- SVII 30.17
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.